The Indian Express •
Gujarat Themis Biosyn (GTBL) plans Rs 3,000 crore acquisitions, including Sanofi's anti-TB brands and Japan's MicroBiopharm, aiming for global pharma growth.
GTBL's acquisitions could boost revenue from Rs 200 crore to Rs 1,300 crore, but execution, debt leverage, and integration risks loom large.